Neurotrophic peptides
The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1), EDQQVHFTPTEG (SEQ ID NO:2) or IPENEADGMPATV (SEQ ID NO:3), and comprising an adamantyl group at the C- and/or N-terminal end.
1. A neurotrophic peptide
consisting of the sequence VGDGGLFEKKL (SEQ ID NO: 1) and
a cycloalkyl or polycycloalkyl group bound to either the C- or N-terminal end of said sequence.
2. The peptide of claim 1 , wherein the cycloalkyl or polycycloalkyl group is an adamantyl group.
3. The peptide of claim 2 , wherein the adamantyl group is adamantyl-L-glycine, adamantyl-L-alanine, an alkylated adamantane group, an isomer of an adamantine, or a di- or triadamantane group.
4. A pharmaceutical composition, comprising:
a peptide fragment consisting of a sequence selected from the group consisting of GDGGLFEK (SEQ ID NO: 5), GLFEKKLW (SEQ ID NO: 6), VGDG (SEQ ID NO: 7), DGGL (SEQ ID NO: 9), and GGLF (SEQ ID NO: 10); and
a cycloalkyl or polycycloalkyl group bound to either the C- or N-terminal end of the fragment.
5. The composition of claim 4 , wherein the cycloalkyl or polycycloalkyl group is an adamantyl group.
6. The composition of claim 5 , wherein the adamantyl group is adamantyl-L-glycine, adamantyl-L-alanine, an alkylated adamantane group, an isomer of an adamantine, or a di- or triadamantane group.
7. The composition of claim 4 , further comprising a pharmaceutically acceptable excipient and/or carrier.
8. The composition of claim 4 , wherein the composition is suitable for intravenous, intramuscular, spinal, epidural, transdermal, subcutaneous, parenteral, intranasal, mucosal, oral, enteral, and/or rectal administration.
9. The composition of claim 4 , further comprising a slow release carrier.
10. The composition of claim 4 , wherein the peptide fragment is dosed in an amount between 0.1 μg/g to 100 mg/g.
11. The composition of claim 10 , wherein the peptide fragment is dosed in an amount between 1 μg to 80 mg/g.
12. A method of treating a subject comprising:
obtaining a pharmaceutical composition comprising a peptide fragment consisting of a sequence selected from the group consisting of GDGGLFEK (SEQ ID NO: 5), GLFEKKLW (SEQ ID NO: 6), VGDG (SEQ ID NO: 7), DGGL (SEQ ID NO: 9), and GGLF (SEQ ID NO: 10) and a cycloalkyl or polycycloalkyl group bound to either the C- or N-terminal end of the fragment; and
providing the composition to a subject;
wherein learning-memory capacity is improved in the subject.
13. The method of claim 12 , wherein the composition further comprises at least one additional pharmaceutically active component.
14. The method of claim 12 , wherein the composition is provided intravenously, intramuscularly, spinally, epidurally, intranasally, mucosally, transdermally, subcutaneously, parenterally, orally, enterally, or rectally.
15. The method of claim 12 , wherein the composition a slow release formulation.
16. The method of claim 12 , wherein the composition comprises the peptide fragment in an amount between 0.1 μg/g to 100 mg/g.
17. The method of claim 16 , wherein the composition comprises the peptide fragment in an amount between preferably 1 μg to 80 mg/g.
18. The method of claim 17 , wherein the peptide fragment is administered to the subject at a dose of 0.1 μg/kg to 20 mg/kg body weight.
19. The method of claim 18 , wherein the peptide fragment is administered to the subject at a dose of 0.5 μg/kg to 10 mg/kg body weight.
20. The method of claim 12 , wherein the subject is a human.